Min Li to Carcinoma, Pancreatic Ductal
This is a "connection" page, showing publications Min Li has written about Carcinoma, Pancreatic Ductal.
Connection Strength
2.390
-
Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer. Clin Cancer Res. 2022 08 02; 28(15):3176-3178.
Score: 0.728
-
A Novel Translational Activation of HIF1a Promotes Pancreatic Cancer Growth Through Glycolytic Reprogramming. Gastroenterology. 2022 04; 162(4):1040-1042.
Score: 0.703
-
Interplay of Tumor Microenvironment Factors and Cancer Stem Cell Enrichment in Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2021 12; 161(6):1800-1802.
Score: 0.685
-
An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. EBioMedicine. 2021 Mar; 65:103271.
Score: 0.165
-
Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling. Cancer Lett. 2015 Apr 10; 359(2):314-24.
Score: 0.108